Protocol Ledger

NCT04776746 · Phase III · TERMINATED

Open-Label Extension Study of Trofinetide for Rett Syndrome

Interventional Phase III clinical trial protocol NCT04776746 sponsored by ACADIA Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-08 Enrollment: 77 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04776746
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)77 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04776746
Protocol FieldVerified Registry Value
NCT IdentifierNCT04776746
Consolidated Lead SponsorACADIA Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment77 participants (ACTUAL)
Registered Start Date2020-11-08
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI